XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

Strategic Acceleration of the Gout Program: XRx-026 and XORLO™ In the first quarter of the year, XORTX pivoted to prioritize and accelerate its gout program, XRx-026, leveraging significant progress in formulation development and clinical validation of its proprietary XORLO™ formulation. XORLO™, an oral oxypurinol formulation, shows increased oral bioavailability, a key differentiator for improved patient outcomes. XORTX is committed to developing a needed gout therapy for patients who are intolerant to exi ...